There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spruce Biosciences (SPRB – Research Report) and Scilex Holding Company (SCLX – Research Report) with bullish sentiments.
Spruce Biosciences (SPRB)
In a report released today, Boobalan Pachaiyappan from H.C. Wainwright reiterated a Buy rating on Spruce Biosciences, with a price target of $10.00. The company’s shares closed last Monday at $2.44.
According to TipRanks.com, Pachaiyappan is a 3-star analyst with an average return of
Spruce Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $8.67, a 267.4% upside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
Scilex Holding Company (SCLX)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Scilex Holding Company today and set a price target of $12.00. The company’s shares closed last Monday at $1.55, close to its 52-week low of $0.90.
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of
Scilex Holding Company has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SPRB: